公开(公告)号：US20240066509A1

公开(公告)日：2024-02-29

申请号：US18232230

申请日：2023-08-09

Applicant: REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Pavel Nagorny ,  Iaroslav Khomutnyk ,  Sibin Wang ,  Oleksii Zhelavskyi

IPC: B01J31/02 ,  B01J31/06 ,  B01J35/02 ,  B01J37/02 ,  C07B51/00 ,  C07D309/10 ,  C07D309/30 ,  C07D493/04

CPC classification number: B01J31/0258 ,  B01J31/06 ,  B01J35/026 ,  B01J37/0219 ,  B01J37/0221 ,  C07B51/00 ,  C07D309/10 ,  C07D309/30 ,  C07D493/04

Abstract: Provided herein are immobilized chiral phosphoric acids and methods of using immobilized chiral phosphoric acids as catalysts for protecting group reactions.

公开(公告)号：US11708319B2

公开(公告)日：2023-07-25

申请号：US17375882

申请日：2021-07-14

Applicant: THE UNIVERSITY OF KANSAS

Inventor： Brian S. J. Blagg ,  Rick T. Dobrowsky ,  Mercy Anyika

IPC: C07D311/12 ,  C07C233/18 ,  C07D309/10 ,  C07H15/203 ,  C07D307/20 ,  C07D311/08 ,  C07D311/16

CPC classification number: C07C233/18 ,  C07D307/20 ,  C07D309/10 ,  C07D311/08 ,  C07D311/16 ,  C07H15/203 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16

Abstract: Provided herein are compounds of the formulas:




wherein: n, X2, R3, R3′, R4, R4′, R5, R5′, R6, and R6′ are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.

公开(公告)号：US20180127391A1

公开(公告)日：2018-05-10

申请号：US15571112

申请日：2016-05-04

Applicant: Glenmark Pharmaceuticals Limited

Inventor： Shekhar Bhaskar Bhirud ,  Kumar Hari BHUSHAN ,  Raghu Ram SURAPARAJU ,  Nandkumar GAIKWAD ,  Sharad GORE ,  Rajendra JAGDHANE ,  Mandar KULKARNI

IPC: C07D309/10 ,  C07C31/20 ,  C07H7/04 ,  C07B51/00 ,  C07B63/04 ,  B01D9/00

CPC classification number: C07D309/10 ,  A61K31/70 ,  B01D9/0054 ,  C07B51/00 ,  C07B63/04 ,  C07C31/207 ,  C07H7/04

Abstract: The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.

公开(公告)号：US09856283B2

公开(公告)日：2018-01-02

申请号：US14847439

申请日：2015-09-08

Applicant: The Regents of The University of California ,  University College Dublin

Inventor： Stefan Oscarson ,  John Vincent Fahy ,  Shaopeng Yuan ,  Stephen Carrington

IPC: C07H15/04 ,  C07H5/04 ,  A61K31/7028 ,  A61K31/70 ,  A61K31/7016 ,  A61K31/702 ,  C07D309/10 ,  C07H13/04

CPC classification number: C07H15/04 ,  A61K31/70 ,  A61K31/7016 ,  A61K31/702 ,  A61K31/7028 ,  C07D309/10 ,  C07H5/04 ,  C07H13/04

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

公开(公告)号：US09834573B2

公开(公告)日：2017-12-05

申请号：US14627693

申请日：2015-02-20

Applicant: Theracos Sub, LLC

Inventor： Mengzhuang Cai ,  Qian Liu ,  Ge Xu ,  Binhua Lv ,  Brian Seed ,  Jacques Y. Roberge

IPC: C07H7/04 ,  C07H1/06 ,  C07D309/10

CPC classification number: C07H1/06 ,  C07D309/10 ,  C07H7/04

Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

公开(公告)号：US09822058B2

公开(公告)日：2017-11-21

申请号：US14390190

申请日：2013-03-13

Applicant: CHDI FOUNDATION, INC.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Leonard Mitchell ,  Peter Johnson ,  Naomi Went

IPC: C07C62/38 ,  C07D307/94 ,  C07D309/10 ,  C07D215/18 ,  C07D311/58 ,  C07D317/46 ,  C07D317/60 ,  C07D319/18 ,  C07D233/64 ,  C07D235/26 ,  C07D403/10 ,  C07D405/08 ,  C07D405/10 ,  C07D405/12 ,  C07C317/44 ,  C07D413/08 ,  C07D413/10 ,  C07C323/62 ,  C07C229/22 ,  C07C229/46 ,  C07C229/48 ,  C07D257/04 ,  C07D203/08 ,  C07D263/58 ,  C07C235/82 ,  C07D207/08 ,  C07D271/07 ,  C07D207/337 ,  C07D295/155 ,  C07D305/06 ,  C07D305/08 ,  C07D307/54 ,  C07D307/80 ,  C07C69/757 ,  C07D203/10 ,  C07D307/79 ,  C07D413/12 ,  C07H15/20

CPC classification number: C07C62/38 ,  C07C69/757 ,  C07C229/22 ,  C07C229/46 ,  C07C229/48 ,  C07C235/82 ,  C07C317/44 ,  C07C323/62 ,  C07C2601/02 ,  C07C2602/50 ,  C07D203/08 ,  C07D203/10 ,  C07D207/08 ,  C07D207/337 ,  C07D215/18 ,  C07D233/64 ,  C07D235/26 ,  C07D257/04 ,  C07D263/58 ,  C07D271/07 ,  C07D295/155 ,  C07D305/06 ,  C07D305/08 ,  C07D307/54 ,  C07D307/79 ,  C07D307/80 ,  C07D307/94 ,  C07D309/10 ,  C07D311/58 ,  C07D317/46 ,  C07D317/60 ,  C07D319/18 ,  C07D403/10 ,  C07D405/08 ,  C07D405/10 ,  C07D405/12 ,  C07D413/08 ,  C07D413/10 ,  C07D413/12 ,  C07H15/20

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US20170247401A1

公开(公告)日：2017-08-31

申请号：US15373260

申请日：2016-12-08

Applicant: Washington University

Inventor： James W. Janetka ,  Zhenfu Han ,  Scott Hultgren ,  Jerome S. Pinkner ,  Corinne Cusumano

IPC: C07H15/20 ,  C07H15/26

CPC classification number: C07H15/20 ,  A01N43/10 ,  A01N43/16 ,  A01N43/38 ,  A01N43/42 ,  A01N43/52 ,  A01N43/54 ,  A01N43/76 ,  A01N43/78 ,  A01N47/36 ,  A01N55/08 ,  A61K31/505 ,  A61K31/7034 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/706 ,  C07D309/10 ,  C07H15/203 ,  C07H15/207 ,  C07H15/22 ,  C07H15/26 ,  C07H19/056

Abstract: The present invention encompasses compounds and methods for treating urinary tract infections.

公开(公告)号：US09745281B2

公开(公告)日：2017-08-29

申请号：US14767762

申请日：2014-02-14

Applicant: GALDERMA RESEARCH & DEVELOPMENT

Inventor： Jean-Guy Boiteau

IPC: C07D335/02 ,  C07D309/06 ,  C07D309/10

CPC classification number: C07D335/02 ,  C07D309/06 ,  C07D309/10

Abstract: A method is described for the synthesis of 4-(heterocycloalkyl)-benzene-1,3-diol compounds of general formulae (I) and (II): wherein X can be an oxygen atom or a sulphur atom. Also described, is a method for the synthesis of the reactive intermediates of general formula (7a) or (7b) Novel compounds as synthesis intermediates are also described.

公开(公告)号：US09682993B2

公开(公告)日：2017-06-20

申请号：US14650826

申请日：2013-12-09

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL

Inventor： Thomas R Webb ,  Chandraiah Lagisetti

IPC: C07D493/10 ,  C07D309/10 ,  A61K31/351

CPC classification number: C07D493/10 ,  A61K31/351 ,  C07D309/10

Abstract: In one aspect, the invention relates to compounds having anticancer activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US09676741B1

公开(公告)日：2017-06-13

申请号：US15321007

申请日：2015-06-23

Applicant: Sun Pharmaceutical Industries Limited

Inventor： Ramkinkar Santra ,  Tarun Kumar Singh ,  Ram Thaimattam ,  Mohan Prasad

IPC: A61K31/70 ,  C07H15/04 ,  C07D309/10 ,  C07C59/265

CPC classification number: C07D309/10 ,  C07B2200/13 ,  C07C59/265

Abstract: The present invention relates to a dapagliflozin-citric acid co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus. A dapagliflozin citric acid co-crystal. The dapagliflozin citric acid co-crystal of claim 1, characterized by X-ray powder diffraction peaks having d-spacing values at about 3.89, 3.90, 4.01, 4.35, 5.77, and 5.80.